Spine BioPharma Announces Investment by Pacira Biosciences
Supports Clinical Advancement of Remedisc™ for Degenerative Disc Disease
News provided by
Share this article
Share this article
NEW YORK, April 20, 2021 /PRNewswire/ Spine BioPharma, LLC, a company committed to developing non-opiate, non-surgical therapies for the treatment of pain and disability from chronic low back pain caused by degenerative disc disease, today announced a $3 million investment by Pacira Biosciences in the form of a convertible note. The investment will support the further development of Remedisc, a first-in-class therapeutic for the treatment of degenerative disc disease. Pacira will make an additional $7 million investment predicated upon achieving certain prespecified milestones.
The Need for Comprehensive Diagnostics Remains as Cases Spike Once More
FinancialBuzz.com News Commentary
Share this article
Share this article
NEW YORK, April 20, 2021 /PRNewswire/ The Director of the U.S. National Institute of Allergy and Infectious Diseases, Dr. Anthony Fauci, and many other experts have warned that rapid reopening and lifting of pandemic restrictions in many states, as well as the proliferation of more contagious variants, will likely result in ongoing and increased spread of the virus in hot spots around the country. The pandemic remains a very real threat as the number of new cases spiked in the United States once again. Dr. Abdul El-Sayed, a former health commissioner for Detroit, explained, according to a report by CNN, that vaccines don t work until they hit people s arms - and we just don t have enough vaccinations in people s arms yet to be able to achieve the kind of herd immunity that we need. Sunshine Biopharma Inc. (OTC: SBFM), Fluidigm Corpor
76% have already received or plan to soon receive the COVID-19 vaccine. Of the remaining
24%, nearly
6 in 10 (
50% is because of the side effects and
20% say it s because of how fast the vaccine was created. Despite the vaccine,
67% think it s too soon to drop mask mandates.
59% are in favor of some kind of vaccine passport. Mask or no mask, vaccine or no vaccine, nearly two-thirds (
62%) in this new normal are afraid to cough or sneeze in public even if it s not because they have COVID-19.
PANDEMIC LIFE SILVER LININGS
There have been some pandemic life positives;
91% say they will miss some aspect of pandemic life. When asked what they will miss most, the top ranked response was family time, with
Share this article
Share this article
FLINT, Mich., April 19, 2021 /PRNewswire/ LifeTime Health Center, a functional medicine practice in Tyler, Texas, and a Forum Health Network Provider welcomes Wade Huey, MD and Rebecca Crowley-Huey, PA-C to its expanding team of functional and integrative medicine providers.
The husband and wife team brings extensive experience in men s and women s personalized health evaluations and treatments with a focus on hormones, sexual health, anti-aging and regenerative medicine.
Dr. Wade Huey
Rebecca Crowley-Huey, PA-C
Dr. Wade Huey earned his medical degree from the University of Texas Health and Science Center at San Antonio Medical School and specializes in preventive medicine, hormone imbalances, and treats symptoms of disease and aging with the use of bioidentical hormone replacement therapy (BHRT) and functional medicine.
Share this article
Share this article
REDWOOD CITY, Calif., April 19, 2021 /PRNewswire/ Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced the appointment of Jon Shear to the newly created position of Vice President, Corporate Development, effective immediately. Jon is uniquely qualified for this new role and brings extensive insight and understanding of the medical technologies industry to Nevro, said D. Keith Grossman, Chairman, CEO and President of Nevro. As a member of our leadership team, he will be responsible for leading Nevro s strategic planning process, overseeing the business development function and driving strong alignment between the company s strategies and its external business development plans as we continue to accelerate toward long-term sustainable growth and strong financial performance for our shareholders. We are delighted to welcome